secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001558370-22-017917
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q3 net loss widens to $3.5M; begins Phase 1/1b for BP1002 in AML
-------------------------------------------------------------------------

- Net loss $3.5M ($0.49/share) vs $2.1M ($0.29/share) in Q3 2021.
- R&D expense doubled to $2.4M on manufacturing costs and BP1001-A trial startup.
- Cash $13.7M at Sep 30, 2022, down from $23.8M at Dec 31, 2021; YTD ops burn $10.1M.
- First patient dosed in Phase 1/1b study of BP1002 for refractory/relapsed AML.
- Closed $2.0M registered direct offering of 800k shares at $2.50 each, with warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/0001558370-22-017917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/bpth-20221115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer